IC-OS International Cardio-Oncology Society

GCOS 2021 - Virtual

30 September

9:00 AM America/New_York


Global Cardio-Oncology Summit will summarize the latest research and best practices in Cardio-Oncology, a multidisciplinary speciality that has gained a growing interest from a large number of healthcare providers including oncologists, cardiologists, radiologists, nurses, pharmacists, and basic scientists. Hand in hand with leading experts, G-COS aims is to improve our knowledge of the role of diagnostic and management tools to mitigate cardiotoxicity risk, while maintaining effective cancer therapies.

IC-OS invites abstract submmissions for the Global Cardio-Oncology Summit 2021 - Virtual on the prevention, management and treatment of cardiac complications related to oncology therapy. Deadline is 1st August 2021

For submissions click here

If you are interested in registering to attend GCOS 2021 - Virtual, or becoming an IC-OS member click here


Alexander Lyon

Dr. Alexander Lyon is a Senior Lecturer in Cardiology at Imperial College London and a Consultant Cardiologist at the Royal Brompton Hospital. His clinical interests are in the field of heart failure, cardio-oncology including chemotherapy cardiomyopathy and the cardiovascular complications of modern cancer therapies, Takotsubo syndrome and the effects of major stresses of the heart, and the development of novel therapeutics including gene therapy for chronic heart failure. Alex has published over 180 scientific papers in peer-reviewed journals, several book chapters in cardiology textbooks including the chapter on cardiotoxicity of tyrosine kinase inhibitors in the latest edition of the ESC Textbook of Cardiology. He is a deputy editor of the European Heart Journal, an associate editor of the European Journal of Heart Failure, international advisor to the journal JACC Cardio-Oncology and his H-index is 44. Alex is the clinical lead for the Cardio-Oncology service at the Royal Brompton Hospital since 2011, specialising in surveillance and cardioprotection from modern cancer drugs, risk stratification and treatment of all cardiac complications of cancer treatment. Alex is the current president of the British Cardio-Oncology Society, recently appointed a board member of International Cardio-Oncology Society (ICOS - 2021), chair-elect European Society of Cardiology (ESC) Council of Cardio-Oncology (2020-2022) and he is the cardiology advisor to the charity Macmillan Cancer. Alex is a co-investigator of the first Leducq Cardio-Oncology Transatlantic Research Network funded from 2020-2025 ($6M). Alex is a co-chair of the first ESC Cardio-Oncology Guideline which will be published in 2022. Alex completed a full 4 year term on the board of the Heart Failure Association of the ESC (2016-2020), and he initiated and was the chair of the Heart Failure Association Cardio-Oncology Study Group. He is a co-author of the ESC Position Statement on Cardio-Oncology, the ESC Cardio-Oncology Council article on the setting up and delivery of Cardio-Oncology services and the 2020 ESMO guidelines on the management of cardiac diseases in cancer patients. He is a member of the International Cardio-Oncology Society and Alex was co-chair of the 2017 Global Cardio-Oncology Summit which hosted 325 specialists from 33 countries at the Royal College of Physicians in London in September 2017.

Ana Barac

Ana Barac, MD PhD is an Associate Professor of Medicine and Oncology at Georgetown University and the director of the MedStar Heart and Vascular Institute's Cardio-Oncology program. She specializes in advanced cardiovascular imaging and cardiovascular care of oncology patients. Dr Barac serves an Associate Editor of JACC Cardio-Oncology and a co-director of the ACC Live Course on Advancing CV Care of Oncology patient. She was the founding Chair of the American College of Cardiology (ACC) Cardio-Oncology Council.

Anne Blaes

Dr. Anne Blaes is an Associate Professor in the Division of Hematology and Oncology at the University of Minnesota. She is the section head of Medical Oncology within this division and is Director of Cancer Survivorship Services and Translational Research within the Masonic Cancer Center. She is an active medical oncologist with a special interest in the late effects of cancer therapy, particularly in the area of cardio-oncology. Her research focuses on designing and implementing strategies to help prevent the long term complications of treatments in our cancer survivors, particularly in the areas of cardiovascular health. She is the Chair for the American Society of Clinical Oncology’s Cancer Survivorship Committee, a member of the Executive Board for the Global Cardiooncology Society, associate editor for JACC Cardio-oncology, section editor for Hem/Onc Today on Survivorship and an active member of the ALLIANCE for Cancer Clinical Trials.

Bonnie Ky

I am a tenured Associate Professor of Medicine and Epidemiology and physician scientist at the University of Pennsylvania. My fundamental goals are to gain insight into the underlying mechanisms and predictors of cancer therapy cardiotoxicity, and to translate this understanding to the clinical care of patients. I lead a highly active NIH-funded translational research program in cardio-oncology and am the PI of multiple investigator-initiated cohort studies and clinical trials focused on the study of the cardiotoxic effects of doxorubicin, trastuzumab, anti-angiogenic tyrosine kinase inhibitors, androgen deprivation therapy, and radiation therapy in breast, renal cell, prostate and lung cancers, and lymphoma patients. My programmatic objectives are to understand how we can improve cardiovascular outcomes in cancer patients by determining individual patient risk, through detailed phenotyping of clinical characteristics, the social determinants of health, biologic markers, and echocardiography-derived measures of myocardial mechanics and function. I also serve as the Director for the Penn Center for Quantitative Echocardiography and the Founding Director of the Penn Cardio-Oncology Translational Center of Excellence and have built a strong, multi-disciplinary collaborative network comprised of highly successful basic, translational, and clinical researchers. I am an invited member of many cardio-oncology expert consensus and research groups within the NIH, FDA, American Society of Clinical Oncology, American College of Cardiology, American Heart Association, and European Society of Cardiology focused on advancing our understanding of cardiovascular disease in the growing cancer population. I am the Inaugural Editor-in-Chief of JACC: CardioOncology, and successfully launched this important scientific and clinical resource. I have specialized expertise in cardio-oncology, epidemiology, the study of biomarkers, and imaging tools to understand cardiac remodeling, function, and risk prediction.

Daniel Lenihan

Dr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, he is intimately involved in the latest treatment trials for cardiac amyloidosis. he recently moved to Washington University in St Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continue to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current President of the International Cardio-Oncology Society (ICOS),www.IC-OS.org, which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

Daniela Cardinale

Dr. Daniela Cardinale is specialized in Cardiology. She holds a PhD in Cardiovascular Physiopathology in 2009. She is currently Director of the Cardioncology Unit of the European Institute of Oncology in Milan. Her professional experience and investigational interests focus on prevention, early detection, monitoring and treatment of cardiotoxicity; screening of cardiotoxicity in patients with cardiac disease; malignant pericardial effusion evaluation and intrapericardial treatment.

Dinesh Thavendiranathan

Dr. Dinesh Thavendiranathan is a cardiologist at the Peter Munk Cardiac Center at the Toronto General Hospital, University of Toronto. He is an Associate Professor of medicine and a Clinician Scientist. Dr. Thavendiranathan’s Clinical work involves cardiac MRI, CT, and echocardiography and Cardio-oncology. He is the Director of the Ted Rogers Program in Cardiotoxicity Prevention. His research focus is in the use of advanced cardiac imaging techniques for detection and management of cardiac toxicity. He holds a Canada Research Chair in Cardio-oncology.

Javid Moslehi

He is a cardiologist and myocyte biologist. his clinical focus is cardio-oncology (the cardiovascular care of cancer patients and cancer survivors). His basic and translational NIH-funded laboratory addresses myocardial responses to various stresses including hypoxia, aging and toxins. Over the last several years, given his clinical interest in cardio-oncology, his laboratory focus has been in delineating the mechanistic underpinnings of cardiovascular toxicities from novel targeted cancer therapies. He believes because of the targeted nature of the toxicities, cardio-oncology can provide insights into novel signalling pathways that are relevant in human cardiovascular biology and pathology. At Vanderbilt, He is an Associate Professor of Medicine, Director of Cardio-Oncology and Co-director of Vanderbilt Program for Optimizing Immuno-oNcology Therapy (V-POINT). He works closely with cardiologists and oncologists, basic, translational researchers and clinicians locally, nationally and internationally. He has also started several collaborations with industry and regulatory bodies (including the US FDA). He was recently named the first chair of the American Heart Association (AHA) cardio-oncology subcommittee. At Vanderbilt, he has established a Graduate Medical Education (GME) approved fellowship training the next generation of physician-scientists in the field of cardio-oncology. He is an elected member of American Society of Clinical Investigation (ASCI).

Joe Carver

Joseph R. Carver, MD, FACC is a Board Certified cardiologist. He is the Founding Editor of the American Journal of Managed Care and was a Senior Corporate Medical Director at Aetna U.S. Healthcare from 1992-2001 where he was responsible for new program development and directed the National Medical Excellence Program. From 1999-2001, he was Co-chairperson of the New Jersey and Michigan Working Groups that established voluntary agreements among the insurers in those states to cover the routine costs of clinical trial participation for cancer patients. He is one of the Founding Editors of Cardio-oncology Journal. He currently is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center. He is the Director of the Thalheimer Cardio-oncology Center at the Abramson Cancer Center and his clinical practice is in the subspecialty of Cardio-oncology. He was the recipient of the IS Ravdin Master Clinician Award at Penn in 2012 and is one of the founding members of Penn Medicine’s Academy of Master Clinicians. He received the Thomas Force Award in 2020.

Joerg Herrmann

Dr. Joerg Herrmann graduated from Ruhr University medical school in Bochum, Germany and completed his internal medicine residency and cardiovascular diseases and interventional cardiology fellowship at the Mayo Clinic in Rochester, MN. Thereafter, he joined the division of cardiovascular diseases at the Mayo Clinic Rochester. He is a Professor of Medicine at the Mayo Clinic College of Medicine and currently serves as the director of the Cardio-Oncology Clinic and the research director of the Ischemic Heart Disease program. His research interests focus on all aspects of cardio-oncology and the pathophysiology, diagnosis, and treatment of atherosclerosis. He has published over 100 articles in peer-reviewed journals and has received NIH grant funding. He also serves as the associated editor of Trends in Cardiovascular Medicine and Practice Update.

Marielle Scherrer-Crosbie

Dr Scherrer-Crosbie is the Director of the Echocardiography Laboratory and a Professor of Medicine at the Hospital of the University of Pennsylvania in Philadelphia, PA, USA. She has a longstanding interest in the interactions of cancer, chemotherapy and heart failure. Throughout her research career, she has also successfully developed a number of novel techniques in the field of echocardiography. She has published over 145 papers and has been continuously funded by the American Heart Association, the American Society of Echocardiography and the NIH. She is involved in the ACC, AHA, APS and ASE, having chaired the cardiovascular sessions at Experimental Biology 2016-2019 and the American Society of Echocardiography 2019 Scientific Sessions. Over the last several years, she has been the PI of 2 multicenter prospective studies, one investigating the value of echocardiographic and blood biomarkers in the prediction of cardiotoxicity in women treated with anthracyclines and trastuzumab, and one investigating the role of statins in the prevention of cardiotoxicity.

Mike Fradley

Dr. Michael Fradley is an Associate Professor of Clinical Medicine in the Division of Cardiology at the Perelman School of Medicine at the University of Pennsylvania and serves as the medical director of the Penn Medicine Cardio-Oncology program. He earned his B.S at Yale University and his MD degree at the Johns Hopkins University School of Medicine. Dr. Fradley completed his residency in internal medicine through the Osler Medical Residency Program at the Johns Hopkins Hospital. He then went on to complete fellowships in both cardiology and electrophysiology at Massachusetts General Hospital. As a trained electrophysioloigst, Dr. Fradley has particular interest in the diagnosis and management of arrhythmic complications associated with traditional and novel cancer therapies. He is a member of the American College of Cardiology Electrophysiology Leadership Council and the IC-OS Board of Directors.

Susan Dent

A professor at Duke Cancer Institute, United States of America. Features in 4 videos on Wondr Medical. Susan Dent generally speaks on Magnetic Resonance (CMR), Cardio-Oncology, Oncology, and Cardio-Oncology.

Teresa Lopez-Fernandez

Teresa López-Fernández is a clinical investigator and consultant cardiologist at La Paz University Hospital in Madrid, Spain. She is specializes in cardiac imaging (she is board certified in advanced and transesophageal echocardiography by the European Society of Cardiology (ESC)) and cardio-oncology (she is board certified by the International Cardio-Oncology Society), and currently coordinates the cardio-oncology team at La Paz University Hospital. She is the founder and chair of the Spanish Cardio-Oncology Working Group at the Spanish Society of Cardiology (SEC) and the Secretary of the ESC Council of Cardio-Oncology.

Thomas H Marwick

Tom Marwick is the Director of Baker Heart and Diabetes Institute. His education was completed at the University of Melbourne, University of Louvain, Belgium and Harvard. His main contributions are in clinical research and research training, and has supervised over 30 research higher-degree students. He was one of the initiators of stress echocardiography, and has made contributions to the prognostic evidence underlying cardiovascular imaging. His main research interests relate to detection of early cardiovascular disease and cost-effective application of cardiac imaging techniques for treatment. He has published over 900 papers, reviews, chapters and editorials, and is an Associate Editor at JACC and Deputy Editor at JACC-Cardiovascular Imaging.

Tomas G. Neilan

Dr. Neilan is an Associate Professor of Medicine at Harvard Medical School, the Clinical Director of the Cardio-Oncology Program at MGH, the co-Director of the Cardiovascular Imaging Research Center, and the PI of the MGH T32 Training Program in Cardiovascular Imaging. He is a physician scientist and a board-certified cardiologist. He completed his medical school training at University College Dublin Medical School, his clinical training in Internal Medicine and Cardiology at the Mater Hospital in Dublin and repeated his training in Internal Medicine and Cardiology at MGH. He has also competed advanced training in Echocardiography at MGH, a three-year Cardiac MRI clinical and research fellowship at BWH and a Master’s in Public Health at the Harvard School of Public Health. His career has had two major focuses: 1) Understanding how we can improve the cardiovascular care of patients with cancer and 2) The use of advanced imaging to better understand and characterize cardiovascular disease. In summary, so far in his career, he has authored or co-authored more than 120 original manuscripts and 30 review articles, presented over 100 abstracts at international meetings, has lectured at major national and international meetings, and received funding from the American Heart Association, American Society of Echocardiography, The National Institutes of Health, MGH Institute for Heart, Vascular and Stroke Care, The Irish Heart Foundation, the Center for AIDS Research and Industry. Dr. Neilan has been awarded the “de Gunzburg Family Endowed Scholar in Cardiology”, The Locke Award for excellence in medical education and elected as a Senior Fellow to the Oliver Wendell Holmes Society, a mentorship program, at Harvard Medical School.


GCOS 2021 - Virtual

Global Cardio-Oncology Summit will summarize the latest research and best practices in Cardio-Oncology, a multidisciplinary speciality that has...
Read More

9:00 AM - 9:15 AM America/New_York

GCOS 2021 Welcome & Introduction

With Anne Blaes, Joe Carver, Mike Fradley, and Susan Dent

Components/UI/Add-Calendar/Calendar-L Add to calendar

9:15 AM - 10:15 AM America/New_York

Session 1 - Looking Towards The Future: Lessons Learned for Cardio-Oncology from the COVID 19 Pandemic

With Larry Shulman

Components/UI/Add-Calendar/Calendar-L Add to calendar

10:15 AM - 11:30 AM America/New_York

Session 2 - Cardio-Oncology Around the Globe

With Andres Daniele, Cafer Zorkun, Daniel Cehic, Kay Sharma, and Sergey Kozhukhov

Components/UI/Add-Calendar/Calendar-L Add to calendar

11:30 AM - 12:45 PM America/New_York

Session 3 - Year in Review: Key Developments in Cardio-Oncology

With Darryl Leong, Evandro de Azambuja, and Giselle Melendez

Components/UI/Add-Calendar/Calendar-L Add to calendar

  • Key developments in cardio-oncology
  • Patient Perspective

12:45 PM - 1:00 PM America/New_York

Lunch break

Components/UI/Add-Calendar/Calendar-L Add to calendar

1:00 PM - 1:45 PM America/New_York

Session 4 - The Art of Engagement

With Juan Lopez-Mattei, Maryam Lustberg, Randall Oyer, and Vijay Rao

Components/UI/Add-Calendar/Calendar-L Add to calendar

1:45 PM - 2:35 PM America/New_York

Session 5 - Keynote Debate: Imaging Guided Cardioprotective Strategies – Ready for Prime Time?

With Anne Blaes, Joe Carver, Mike Fradley, Susan Dent, and Thomas H Marwick

Components/UI/Add-Calendar/Calendar-L Add to calendar

  • SUCCOR trial
  • Discussion
  • Closing Remarks

9:00 AM - 9:15 AM America/New_York

Opening Remarks and Day 1 Overview

With Anne Blaes, Joe Carver, Mike Fradley, and Susan Dent

Components/UI/Add-Calendar/Calendar-L Add to calendar

9:15 AM - 9:20 AM America/New_York

Patient Perspective

Components/UI/Add-Calendar/Calendar-L Add to calendar

9:20 AM - 10:15 AM America/New_York

Session 6 - The Cardio-Oncology Team

With Anecita Fadol, Heather Moore, and Scott Adams

Components/UI/Add-Calendar/Calendar-L Add to calendar

10:15 AM - 11:15 AM America/New_York

Session 7 - “How Do I…” Fireside Chats

With Ana Barac, Chau Dang, Jennifer Ligibel, Kerry Reynolds, Kevin Oeffinger, Linda Jacobs, Mike Fradley, Sebastian Szmit, Stephen Schuster, Susan Gilchrist, Tomas Neilan, and Vivek Narayan

Components/UI/Add-Calendar/Calendar-L Add to calendar

Session A

  • How Do I Manage Atrial Fibrillation in Patients with Cancer?

  • How Do I Integrate Cardiac Rehabilitation and Exercise into Survivorship Care?

  • How Do I Diagnose...
Read More

11:15 AM - 11:30 AM America/New_York


Components/UI/Add-Calendar/Calendar-L Add to calendar

11:30 AM - 11:45 AM America/New_York

Session 8 - Thomas Force Memorial

With Bonnie Ky

Components/UI/Add-Calendar/Calendar-L Add to calendar

11:45 AM - 12:15 PM America/New_York

Session 9 - Developing Careers in Cardio-Oncology

With Alexander Lyon, Anne Blaes, Ariane Macedo, Benedicte Lefebvre, Charles Porter, Charlotte Manisty, Daniel Addison, Daniela Cardinale, Husam Abdel-Qadir , Javid Moslehi, Joe Carver, Joshua Mitchell, Lova Sun, Mary Branch, Sarju Ganatra, Shruti Patel, and Susan Dent

Components/UI/Add-Calendar/Calendar-L Add to calendar

Breakout Session – attendees choose 1

  • Fellowship Training Programs in Cardio-Oncology
  • Leveraging ICOS for Career Development
  • Career Pathways in Cardio-Oncology

12:15 PM - 1:00 PM America/New_York

Session 10 - Young Investigator Presentations

With Arjun Ghosh, Avirup Guha, Kathryn Ruddy, Richard Cheng, and Rupal O’Quinn

Components/UI/Add-Calendar/Calendar-L Add to calendar

1:00 PM - 1:45 PM America/New_York

Session 11 - IC-OS 2021 and Beyond

With Anju Nohria , Anne Blaes, Christine Brezden-Masley, Dinesh Thavendiranathan, Joe Carver, Lauren Baldassarre, Mike Fradley, Roohi Ismail-Khan , and Susan Dent

Components/UI/Add-Calendar/Calendar-L Add to calendar

  • Role of ICOS
  • Closing Remarks